(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on outsourced, AI-enabled screening for complex diseases, using automation, miniaturized assays, label-free tools and faster hit-to-lead discovery.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "High-Throughput Screening Services Market Report 2026" has been added to ResearchAndMarkets.com's offering.
High-Throughput Screening Services Market to Reach $39.06 Billion by 2030 as Drug Discovery Investment Accelerates
The global high-throughput screening services market is experiencing rapid growth as pharmaceutical and biotechnology companies increase investments in advanced drug discovery technologies. The market is projected to expand from $23.02 billion in 2025 to $25.54 billion in 2026, representing a compound annual growth rate (CAGR) of 11%. Historical growth has been supported by expanding pharmaceutical research and development, wider use of combinatorial chemistry libraries, adoption of automated liquid-handling systems, demand for faster target identification, and increased availability of large compound libraries.
Looking ahead, the high-throughput screening services market is forecast to reach $39.06 billion by 2030, growing at a CAGR of 11.2%. Key growth drivers include rising investment in precision drug discovery, greater research into biologics and complex therapeutic targets, expansion of personalized medicine, increased use of artificial intelligence in screening workflows, and continued outsourcing of drug discovery activities to contract research organizations.
Prominent high-throughput screening market trends include the adoption of automated robotic platforms, growing demand for ultra-high-throughput screening, and wider use of cell-based and label-free assays. AI-powered data analysis is also becoming increasingly important as researchers seek to process larger datasets, identify promising compounds more efficiently, and shorten hit-to-lead timelines. These advances are helping pharmaceutical and biotechnology organizations improve screening accuracy while accelerating early-stage drug development.
The increasing prevalence of chronic and complex diseases is a major factor supporting market expansion. Aging populations, lifestyle-related risk factors, and improvements in disease detection are contributing to a growing global disease burden and increasing demand for innovative therapies. High-throughput screening services allow researchers to evaluate extensive compound libraries against relevant biological targets, supporting target identification and the discovery of potential treatments for multifactorial and long-term conditions.
According to data published by the U.S. Centers for Disease Control and Prevention in April 2025, approximately 76.4% of adults in the United States-more than 194 million people-reported having at least one chronic condition in 2023. In addition, 51.4% of adults, or around 131 million people, reported having multiple chronic conditions. This rising prevalence is increasing pressure on healthcare systems and reinforcing the need for faster, more efficient drug discovery and development processes.
Innovation in miniaturized, high-density assays is further reshaping the high-throughput screening services market. Advanced platforms with ultra-high screening speeds and as many as 27 detection channels enable researchers to conduct large-scale, multiparametric analyses while improving data output and operational efficiency. In May 2024, Evotec SE introduced comprehensive high-throughput screening services through its integrated early discovery platform. The offering supports large-scale biochemical and cell-based screening campaigns using automated, miniaturized assay systems and advanced analytics to improve hit identification and lead selection.
Strategic acquisitions are also strengthening service capabilities across the industry. In January 2023, Charles River Laboratories International Inc. acquired SAMDI Tech Inc. for an undisclosed amount. The transaction added proprietary label-free, mass spectrometry-based high-throughput screening technologies to Charles River's drug discovery operations. The expanded capabilities are intended to support faster hit identification, higher-quality data generation, and shorter early-stage drug development timelines.
Tariffs are affecting the high-throughput screening services market by raising the cost of imported robotic systems, detection instruments, assay reagents, microplates, and high-performance computing infrastructure. Pharmaceutical and biotechnology hubs in North America and Europe are particularly exposed because of their reliance on advanced imported laboratory equipment. Asia-Pacific is also experiencing higher costs associated with service expansion and export-oriented instrument manufacturing. Although these pressures may increase service prices and extend project timelines, they are encouraging local instrument assembly, regional reagent production, and greater adoption of software-driven screening efficiencies.
Markets Covered:
1) By Products and Services: Instruments; Reagents and Kits; Services
2) By Technology: Ultra-high-throughput Screening; Cell-based Assays; Lab-on-a-chip; Label-free Technology
3) By Application: Target Identification; Primary Screening; Toxicology
4) By End User: Pharmaceutical and Biotechnology Firms; Academia and Research Institutes; Contract Research Organizations
Subsegments:
1) By Instruments: Automated Screening Systems; Liquid Handling Systems; Detection and Imaging Systems; Data Acquisition Systems
2) By Reagents and Kits: Assay Reagents; Screening Kits; Cell Based Reagents; Detection Reagents
3) By Services: Assay Development and Optimization Services; Primary Screening Services; Hit Confirmation and Validation; Data Analysis and Bioinformatics Support; Specialized Screens; Project Management and Reporting
Time Series:
Five years historic and ten years forecast.
Data:
Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation:
Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment